Medicare IVIG Access Enhancement Act of 2023

Bill: 118-hr-5818
Sponsor: full_name: Rep. Smith, Adrian [R-NE-3]
Introduced: 2023-09-28
Policy area: Health
Subjects: Drug therapy

Health care costs and insurance

Health care coverage and access

Medicare

Neurological disorders
Latest action: action_date: 2024-12-17
text: Referred to the Subcommittee on Health.

Summaries:

tv_txt: I 118th CONGRESS 1st Session H. R. 5818 IN THE HOUSE OF REPRESENTATIVES September 28, 2023 Mr. Smith of Nebraska (for himself and Mr. Garamendi ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

1. Short title This Act may be cited as the Medicare IVIG Access Enhancement Act of 2023 . 2. Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program (a) In general Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ) is amended— (1) in subsection (s)(2)(Z), by inserting (and, beginning January 1, 2026, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) after primary immune deficiency diseases ; and (2) in subsection (zz), by inserting (or, beginning January 1, 2026, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) after primary immune deficiency disease . (b) Authority for variance in payments Section 1842(o)(8) of the Social Security Act ( 42 U.S.C. 1395u(o)(8) ) is amended by inserting and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking) after of 2012 .